{"id":"NCT00657709","sponsor":"Novartis Vaccines","briefTitle":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","officialTitle":"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2008-04-14","resultsPosted":"2015-04-10","lastUpdate":"2017-10-10"},"enrollment":3630,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Serogroup B Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)","otherNames":[]},{"type":"BIOLOGICAL","name":"Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)","otherNames":[]},{"type":"BIOLOGICAL","name":"Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix Hexa","otherNames":[]},{"type":"BIOLOGICAL","name":"Menjugate","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar","otherNames":[]}],"arms":[{"label":"rMenB Lot1","type":"EXPERIMENTAL"},{"label":"rMenB Lot2","type":"EXPERIMENTAL"},{"label":"rMenB Lot3","type":"EXPERIMENTAL"},{"label":"Routine","type":"ACTIVE_COMPARATOR"},{"label":"MenC + Routine","type":"ACTIVE_COMPARATOR"}],"summary":"The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vaccines.","primaryOutcome":{"measure":"The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination","timeFrame":"one month after the third vaccination","effectByArm":[{"arm":"rMenB Lot1","deltaMin":1.21,"sd":null},{"arm":"rMenB Lot2","deltaMin":1.19,"sd":null},{"arm":"rMenB Lot3","deltaMin":1.19,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"55 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":66,"countries":["Austria","Czechia","Finland","Germany","Italy"]},"refs":{"pmids":["31110098","23324563"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":70,"n":832},"commonTop":["Irritability","Injection site erythema","Somnolence","Injection site pain","Crying"]}}